




# Full Year and Q4 2024 Results

Conference call and webcast for  
investors and analysts

06 February 2025



# Forward-looking statements

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words ‘anticipates’, ‘believes’, ‘expects’, ‘intends’ and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group’s products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; the risk of foreign exchange rate movements impacting our financial condition or results of operations; and the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.



# Q4 and FY 2024 Results

## Conference call agenda

### CEO Opening Remarks

**Pascal Soriot**

Chief Executive Officer

### Financial Results

**Aradhana Sarin**

Chief Financial Officer

### Oncology

**Dave Fredrickson**

EVP, Oncology Haematology Business

**Susan Galbraith**

EVP, Oncology Haematology R&D

### BioPharmaceuticals

**Ruud Dobber**

EVP, BioPharmaceuticals Business

**Sharon Barr**

EVP, BioPharmaceuticals R&D

### Rare Disease


**Marc Dunoyer**


Chief Executive Officer, Alexion

### CEO Closing Remarks, Q&A

**Pascal Soriot**

Chief Executive Officer






# CEO Opening Remarks

**Pascal Soriot**  
CHIEF EXECUTIVE OFFICER



# Remarkable execution across key fundamentals in FY 2024



Delivered on upgraded FY 2024 financial guidance

9 positive high-value Phase III trial readouts in 2024<sup>1</sup>

8 NME approvals towards ambition of 20 by 2030<sup>2</sup>

**+21%** Total Revenue (vs FY 2023)

**+19%** Core EPS (vs FY 2023)

**+14%** OpEx (vs FY 2023)

Multiple blockbuster opportunities with **combined PYR >\$5bn**

 Kavigale **DATROWAY**


**2 NME approvals since Q3 2024**




# FY 2024 – strong global growth across focus therapy areas

## Broad-based, diverse source of Total Revenue

FY 2024 | % Total Revenue by therapy area




FY 2024 | % Total Revenue by geography




## Strength across therapy areas

FY 2024 | Total Revenue





## Growth across geographies

FY 2024 | Total Revenue



# Sustained, durable growth across Emerging Markets

## Accelerating Emerging Markets growth<sup>1</sup>



Emerging Markets – 67% of global population<sup>2</sup>

Healthcare expenditure increasing and access improving<sup>3</sup>






AstraZeneca sustained presence is a competitive advantage

**Leading multinational pharmaceutical company in Emerging Markets**



# Entering remarkably catalyst-rich 2025

## Key indication expansion opportunities in high-value tumour types or diseases

	<b>Breast cancer</b>	<b>Enhertu</b> HER2+ 1L and early-stage	<b>Datroway</b> 1L TNBC
	<b>Lung cancer</b>	<b>Datroway</b> 1L NSQ/NSQ TROP2+ NSCLC	
	<b>Bladder cancer</b>	<b>Imfinzi ± Imjudo</b> MIBC, NMIBC and unresectable UC	
	<b>Asthma</b>	<b>Breztri</b> Severe asthma	
	<b>COPD</b>	<b>Fasenra</b> COPD	

H1 2025

**eneboparatide** | hypoPT

H2 2025

**camizestrant** | HR+/HER2- BC

**ceralasertib** | post-IO NSCLC

**baxdrostat** | uHTN

**anselamimab** | AL amyloidosis

**efzimfotase alfa** | HPP

**gefurulimab** | gMG


First Phase III data for 7 NMEs in 2025





# Financial Results

**Aradhana Sarin**  
CHIEF FINANCIAL OFFICER



# FY and Q4 2024 – Reported profit and loss

	<b>FY 2024 \$m</b>	<b>CER change %</b>	<b>% Total Revenue</b>	<b>Q4 2024 \$m</b>	<b>CER change %</b>	<b>% Total Revenue</b>
<b>Total Revenue</b>	<b>54,073</b>	<b>21</b>	<b>100</b>	<b>14,891</b>	<b>25</b>	<b>100</b>
- Product Sales	50,938	19	94	13,362	19	90
- Alliance Revenue	2,212	55	4	714	69	5
- Collaboration Revenue	923	54	2	815	>2x	5
Product Sales Gross Margin <sup>1</sup>	80.0%	-1pp		79.6%	+1pp	
Total operating expense <sup>2</sup>	(34,115)	12	63	(10,230)	19	69
- R&D expense	(13,583)	25	25	(4,677)	52	31
- SG&A expense	(19,977)	5	37	(5,410)	1	36
Other operating income and expense	252	(81)	-	100	(6)	1
Operating profit	10,003	32	18	2,036	79	14
Tax rate	19%			10%		
<b>Reported EPS</b>	<b>\$4.54</b>	<b>29</b>		<b>\$0.97</b>	<b>71</b>	



# FY and Q4 2024 – Core profit and loss

	<b>FY 2024 \$m</b>	<b>CER change %</b>	<b>% Total Revenue</b>	<b>Q4 2024 \$m</b>	<b>CER change %</b>	<b>% Total Revenue</b>
<b>Total Revenue</b>	<b>54,073</b>	<b>21</b>	<b>100</b>	<b>14,891</b>	<b>25</b>	<b>100</b>
- Product Sales	50,938	19	94	13,362	19	90
- Alliance Revenue	2,212	55	4	714	69	5
- Collaboration Revenue	923	54	2	815	2x	5
Product Sales Gross Margin <sup>1</sup>	81.2%	-		79.0%	-	
Total operating expense <sup>2</sup>	(27,794)	14	51	(7,991)	13	54
- R&D expense	(12,211)	19	23	(3,573)	22	24
- SG&A expense	(15,028)	11	28	(4,275)	7	29
Other operating income and expense	250	(81)	-	101	(6)	1
Operating profit	16,928	22	31	4,199	58	28
Tax rate	19%			16%		
<b>Core EPS</b>	<b>\$8.21</b>	<b>19</b>		<b>\$2.09</b>	<b>49</b>	




# FY 2025 guidance

Net cash inflow from operating activities increased by 15% in 2024

Net debt/Adjusted EBITDA 1.5x

FY 2025 guidance (CER)



## Total Revenue

anticipated to increase by a **high single-digit** percentage

## Core EPS

anticipated to increase by a **low double-digit** percentage

- Core tax rate expected to be between 18-22%
- Anticipated FX impact – low single-digit adverse impact on Total Revenue and mid single-digit impact on core EPS<sup>4</sup>

**FY 2024 dividend increased 7%, intention to further increase FY 2025 dividend by 3% to \$3.20**

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible assets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), movement in profit participation liability, purchase and disposal of non-current asset investments, payments to associates and joint ventures, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt, payment of contingent consideration on business combinations and payment of Acerta Pharma share purchase liability. The Company uses Debt issuance to finance new Business Development opportunities. 3. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion (FY 2023: \$114m). AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook positive. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 4. If foreign exchange rates for February 2025 to December 2025 were to remain at the average rates seen in January 2025. Appendix: [Glossary](#).



# Diverse global manufacturing footprint

CapEx investment to support sustained long-term growth




Strategic investment  
in key regions

Resilient, dual-source  
supply chain

Focused investment in  
transformative technologies





# Oncology

**Dave Fredrickson**

ONCOLOGY HAEMATOLOGY BUSINESS


**Susan Galbraith**

ONCOLOGY HAEMATOLOGY R&D



# Oncology – FY and Q4 2024

Multiple medicines achieved new multi-blockbuster levels in FY 2024



## Q4 2024: key dynamics


- **Tagrisso** +21%, strong demand across indications, partly offset by hospital ordering dynamic in CN
  - **Calquence** +20%, sustained BTKi leadership in CLL in US and major markets
  - **Imfinzi** +18%, strong demand growth in US, EU; continued JP repricing impact
  - **Imjudo** +28%, durable demand across indications
  - **Lynparza PS** +15%, sustained global PARPi leadership
  - **Enherthu** +54%, continued demand across HER2+ and HER2-low breast, partly offset by post-NRDl inventory drawdown in CN
  - **Truqap** \$163m, market leader in 2L biomarker-altered population
- 
- **Significant regulatory progress:** US (*Enherthu* DESTINY-Breast06, *Datroway* TROPION-Breast01, *Calquence* ECHO, *Imfinzi* ADRIATIC), EU (*Tagrisso* LAURA), JP (*Datroway* TROPION-Breast01, *Imfinzi* ± *Lynparza* DUO-E), CN (*Lynparza* OlympiA, *Tagrisso* LAURA, *Orpathys*)
  - US Priority Review (*Datroway* TROPION-Lung05, *Imfinzi* NIAGARA)



# Oncology – key drivers in 2025

Strong *Tagrisso*, *Enhertu*, *Imfinzi* growth momentum

STRATEGIC EXPANSION



2025 growth driven by continued global expansion and new launch opportunities



# Oncology – select Phase III readouts in 2025

Indication expansion and NME Phase III trials expand ambition in key tumour types

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk

AVANZAR (NSCLC)

TROPION-Breast02 (TNBC)

**ENHERTU**<sup>®</sup>  
fam-trastuzumab deruxtecan-nxki

DESTINY-Breast09 (HER2+)

DESTINY-Breast11 (HER2+)

DESTINY-Breast05 (HER2+)

**IMFINZI**<sup>®</sup>  
durvalumab


VOLGA (MIBC)

POTOMAC (NMIBC)

MATTERHORN (GC/GEJ)


## camizestrant potential best-in-class next generation SERD with differentiated programme in HR+ HER2- breast cancer

- Improved PFS vs. fulvestrant (HR 0.58)
- Efficacy regardless of *ESR1m* status
- Low discontinuation rates
- Ability to combine with all three CDK4/6i



**SERENA-6 first camizestrant Phase III readout in H2 2025**





# BioPharmaceuticals

**Ruud Dobber**

BIOPHARMACEUTICALS BUSINESS

**Sharon Barr**

BIOPHARMACEUTICALS R&D




# BioPharmaceuticals – FY and Q4 2024

Total Revenue \$21.9bn, +21%, strong momentum from multiple medicines


## CVRM

FY 2024 \$12.5bn, +20%



## R&I

FY 2024 \$7.9bn, +25%



## Q4 2024: key dynamics

- **Farxiga** +22%, global demand growth
- **Lokelma** +35%, market share leadership
- **Fasenna** +12%, sustained IL-5 leadership
- **Breztri** +29%, share gains and class expansion
- **Tezspire** +85%, share gains and EU launches
- **Saphnelo** +65%, gains in i.v. segment
- **V&I** +55%, *Beyfortus* >3x
  - V&I FY 2024 \$1.5bn, +8%



# BioPharma – key growth drivers in 2025

Significant potential as more patients move onto guideline-based therapies

STRATEGIC EXPANSION

  
farxiga®  
(dapagliflozin)

- Guidelines continue to drive SGLT2i class expansion
- Continued growth despite anticipated China VBP

Farxiga provides foundation for dapagliflozin FDCs in development

 **LOKELMA**®  
(sodium zirconium cyclosilicate)

- Sustained market leader in K+ Binder class

Further expansion into nephrology, cardiology and primary care

Respiratory inhaled

 **BREZTRI**®  
AEROSPHERE®  
budesonide / glycopyrronium / formoterol fumarate dihydrate pressurized inhalation suspension

- COPD guidelines accelerating adoption of triple therapy
- Further expansion in Emerging Markets

Potential to expand into asthma  
**KALOS | LOGOS**

Respiratory biologics

 **Fasenra**®  
(benralizumab)  **TEZSPIRE**®  
(tezepelumab-ekko)

- *Fasenra* Emerging Markets launch momentum
- *Tezspire* continued asthma growth

Multiple COPD Phase III trials ongoing or planned

 **Saphnelo**™  
(anifrolumab-fnia)

- Continued share gains in i.v. settings

Potential s.c. formulation and indication expansion  
**TULIP SC | IRIS | DAISY**



# BioPharma – select Phase III readouts in 2025

Meaningful indication expansion and high-value NME opportunity

Strengthening industry-leading COPD and asthma portfolio with indication expansion opportunities

baxdrostat potential best-in-class novel medicine for the treatment of hard-to-treat hypertension



## KALOS/LOGOS

expanding into asthma pre-biologics market



## RESOLUTE

potential to address high unmet need in COPD patients with baseline EOS >300

Once-daily dosing with 24-hour control of SBP

11mm Hg SBP reduction observed in Phase II BrigHTN

No observed effects on cortisol, low rate of reported hyperkalaemia

## Robust Phase III programme

### BaxHTN

Phase III designed to show effect on SBP at Week 12

### Bax24

supportive Phase III designed to demonstrate 24-hour control of SBP

AZD0780 (oPCSK9) Phase IIb PURSUIT data to be presented at ACC 2025





# Rare Disease


**Marc Dunoyer**

CHIEF EXECUTIVE OFFICER, ALEXION



# Rare Disease – FY and Q4 2024

Total Revenue +16% in 2024 driven by growing demand for key medicines



## Q4 2024: key dynamics

### C5 Franchise: continued sustainable growth

- **Ultomiris** +33%, driven by demand growth in neurology indications (gMG, NMOSD)
- **Soliris** (22%), successful conversion to *Ultomiris* and biosimilar pressure in EU, partly offset by growth in Emerging Markets

### Beyond Complement: market expansion and increased demand

- **Strensiq** +37% and **Koselugo PS** +97%, driven by continued global demand and some tender order timing in Emerging Markets



# Rare Disease – key growth drivers in 2025

Increasing momentum with *Ultomiris*, *Strensiq* and *Koselugo*

STRATEGIC EXPANSION



- Continued growth in neurology indications driven by new to branded medicines and *Soliris* switch patients
- Launches in new markets

Indication expansion to unlock new growth opportunities  
**HSCT-TMA | CSA-AKI | IgAN**



- HPP guidelines driving increased diagnosis rates and accelerating new patients starts
- Focused on disease education, priming markets ahead of next-generation efzimfotase alfa launch

Building on *Strensiq* foundation with efzimfotase alfa to address broader HPP population



- Continued growth driven by patient demand and geographic expansion in paediatric patients with NF1-PN

Label expansion into adult NF1-PN patients  
**KOMET**




# Rare disease – Phase III readouts in 2025

First Phase III data for 4 potential NMEs

<b>eneboparatide</b> CALYPSO   HypoPT	<b>anselamimab</b> CAEL-301/2   AL-A	ACCELERATED <b>efzimfotase alfa</b> HICKORY/CHESTNUT   HPP	ACCELERATED <b>gefurulimab</b> PREVAIL   gMG	<b>Ultomiris</b> TMA-313/4   HSCT-TMA
PTH1 receptor agonist peptide	Novel depleter mAb	Enzyme replacement Fc fusion protein	V <sub>H</sub> H C5 inhibitor	C5 inhibitor mAb
Potential to normalise serum calcium levels, decrease urinary calcium, preserve bone mineral density	Aims to remove accumulation of fibrils in organs, particularly in the heart and kidneys	Next generation therapy with the potential to address 6x patient population vs. <i>Strensiq</i>	Convenient QW self-administrative s.c. to treat earlier and broader population	Ability to address life-threatening complication of stem cell transplant
H1 2025	H2 2025			

Delivering next-wave of pipeline innovation in complement biology and beyond





# CEO Closing Remarks

**Pascal Soriot**  
CHIEF EXECUTIVE OFFICER



# 2025 outlook supports delivery of strategic ambitions



## Sustained commercial momentum

- Growing demand for medicines substantially offsets IRA and China VBP
- 9 high-value launches in 2025, with combined PYR >\$5bn<sup>1</sup>



## Broad-based global business

- Growth momentum across key regions, notably US
- Diverse global manufacturing supports in-market supply




## Pipeline execution

- First Phase III data for 7 NMEs
- Multiple high-value indication expansion opportunities

**Sustained global demand growth and an unprecedented catalyst-rich 2025**



# Significant progress with transformative technologies to drive 2030+ growth



**ADCs/RCs, next-gen IO and cell therapy/TCE progressed to Phase III**



# On track to deliver on 2030 ambitions supported by strong momentum and catalyst-rich 2025



Ambition to deliver **\$80bn in Total Revenue by 2030<sup>1</sup>**

Strong growth in 2025 with global medicines demand substantially offsetting anticipated headwinds



On track to deliver **mid-30s% Core operating margin by 2026**


Growth in SG&A slower than Total Revenue  
R&D to remain low 20% of Total Revenue



Ambition to deliver **at least 20 NMEs by 2030**

8 NMEs launched to date and first Phase III data for 7 NMEs expected in 2025





# Appendix



# Appendix – 9 high-value positive Phase III trials in 2024



## LAURA | Stg III u/r NSCLC

Expanding *Tagrisso* as backbone TKI in early-stage NSCLC



## ECHO | MCL

*Calquence* first BTKi to show favourable overall survival trend



## AMPLIFY | CLL

Securing *Calquence* leadership with finite treatment option



## DESTINY-Breast06 | mBC

*Enhertu* moving into CTx naïve mBC, benefit in HER2-ultralow



## CAPitello-281 | dPTEN mHSPC

*Truqap* first and only AKT inhibitor to show statistically significant, clinically meaningful improvement in rPFS



## ADRIATIC | LS-SCLC

*Imfinzi* first and only IO to show survival benefit in LS-SCLC



## NIAGARA | MIBC

*Imfinzi* first perioperative IO regimen to extend survival in muscle-invasive bladder cancer



## WAYPOINT | CRSwNP

*Tezspire* first TSLP mAb to show benefit in nasal polyps



## KOMET | adult NF1-PN

*Koselugo* extends strong clinical benefit to adult patient population with high unmet need

■ Oncology ■ BioPharma ■ Rare Disease

Multiple blockbuster opportunities with **combined peak year revenue >\$5bn<sup>1</sup>**



# Appendix – entering remarkably catalyst-rich 2025

Multiple indication expansion opportunities for existing medicines and first Phase III data for 7 NMEs

## Select Phase III data for existing medicines

**Datroway** | lung and breast cancer

**AVANZAR, TROPION-Breast02**

**Enhertu** | HER2+ breast cancer

**DESTINY-Breast09, -11, -05**

**Imfinzi** | bladder cancer

**VOLGA, POTOMAC, NILE**

**Breztri** | severe asthma

**KALOS/LOGOS**

**Fasenra** | COPD

**RESOLUTE**

## First Phase III data for NMEs

**camizestrant**  
ngSERD

**SERENA-6** (HR+/HER2- mBC)

**ceralasertib**  
ATR inhibitor

**LATIFY** (post-IO NSCLC)

**baxdrostat**  
ASI

**BaxHTN** (uHTN)

**anselamimab**  
AL depleter

**CAEL101-301/2** (AL amyloidosis)

**efzimfotase alfa**  
enzyme replacement

**HICKORY/CHESTNUT** (HPP)

ACCELERATED

**eneboparatide**  
PTHr1 agonist peptide

**CALYPSO** (hypoparathyroidism)

**gefurulimab**  
s.c. C5 mAb

**PREVAIL** (gMG)

ACCELERATED



# Appendix – AstraZeneca P&L reference table

## P&L line-item definitions


	P&L line-item definition
<b>Product Sales</b>	<ul style="list-style-type: none"><li>• Recognises sales from territories where Group has lead commercialisation</li><li>• Recognises supply of <i>Beyfortus</i> to Sanofi</li></ul>
<b>Alliance Revenue</b>	<ul style="list-style-type: none"><li>• Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place<sup>1</sup></li></ul>
<b>Collaboration Revenue</b>	<ul style="list-style-type: none"><li>• Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product</li></ul>
<b>Total Revenue</b>	<ul style="list-style-type: none"><li>• Sum of Product Sales, Alliance Revenue and Collaboration Revenue</li></ul>
<b>Product Sales Gross Margin</b>	<ul style="list-style-type: none"><li>• Calculated by dividing the difference between Product Sales and Cost of Sales by the Product Sales</li><li>• Excludes the impact of Alliance Revenue and Collaboration Revenue</li></ul>
<b>Other operating income &amp; expense</b>	<ul style="list-style-type: none"><li>• Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest</li></ul>
<b>Core Operating margin</b>	<ul style="list-style-type: none"><li>• Defined as Core Operating profit as a percentage of Total Revenue</li></ul>



# Oncology


## Tagrisso

16% growth at CER to \$6,580m in FY 2024



## Lynparza (Product Sales)


11% growth at CER to \$3,072m in FY 2024



# Oncology


## Imfinzi

21% growth at CER to \$4,717m in FY 2024



## Imjudo


31% growth at CER to \$281m in FY 2024



# Oncology


## Calquence

25% growth at CER to \$3,129m in FY 2024



## Enhertu


58% growth at CER to \$1,982m in FY 2024



# BioPharmaceuticals: Cardiovascular, Renal & Metabolism


## Farxiga

31% growth at CER to \$7,717m in FY 2024




## Brilinta

2% growth at CER to \$1,333m in FY 2024



## Lokelma


34% growth at CER to \$542m in FY 2024



# BioPharmaceuticals: Respiratory & Immunology


## Fasenra

9% growth at CER to \$1,689m in FY 2024




## Breztri

46% growth at CER to \$978m in FY 2024



## Tezspire


2x growth at CER to \$684m in FY 2024



# BioPharmaceuticals: Respiratory & Immunology


## Symbicort

25% growth at CER to \$2,879m in FY 2024



## Pulmicort


1% decrease at CER to \$682m in FY 2024



# Rare Disease


## Ultomiris

34% growth at CER to \$3,924m in FY 2024




## Strensiq

24% growth at CER to \$1,416m in FY 2024



## Koselugo (Product Sales)

66% growth at CER to \$531m in FY 2024



# Glossary

<b>1L, 2L, 3L</b>	first-, second-, third-line	<b>ESR1m</b>	estrogen receptor alpha-mutated	<b>NMOSD</b>	neuromyelitis optica spectrum disorder
<b>AAV</b>	adeno-associated virus	<b>ET</b>	endocrine therapy	<b>NRDL</b>	national reimbursement drug list
<b>abema</b>	abemaciclib	<b>EU</b>	Europe	<b>NSCLC</b>	non-small cell lung cancer
<b>ACC</b>	American College of Cardiology	<b>FDC</b>	fixed-dose combination	<b>NSQ</b>	non-squamous
<b>ADC</b>	antibody-drug conjugate	<b>fulvestrant</b>	Faslodex	<b>oGLP-1</b>	oral glucagon-like peptide-1
<b>AKT</b>	protein kinase B	<b>FX</b>	foreign exchange	<b>P&amp;L</b>	Profit & Loss
<b>AL</b>	light-chain	<b>FY</b>	Full Year	<b>palbo</b>	palbociclib
<b>AL amyloidosis</b>	light-chain amyloidosis	<b>GC</b>	gastric cancer	<b>PARPi</b>	poly-ADP ribose polymerase inhibitor
<b>AL-A</b>	light-chain amyloidosis	<b>GEJ</b>	gastroesophageal junction	<b>PD-1</b>	programmed cell death protein-1
<b>API</b>	active pharmaceutical ingredient	<b>GI</b>	gastrointestinal	<b>PD-L1</b>	programmed cell death ligand 1
<b>ASI</b>	aldosterone synthase inhibitor	<b>gMG</b>	generalised myasthenia gravis	<b>PFS</b>	progression free survival
<b>ATR</b>	ataxia telangiectasia and Rad3-related protein	<b>GU</b>	genitourinary	<b>PS</b>	Product Sales
<b>BC</b>	breast cancer	<b>HER2-</b>	human epidermal growth factor receptor 2	<b>PSMA-positive</b>	prostate specific membrane antigen-positive
<b>BCMA</b>	B-cell maturation antigen	<b>HER2+</b>	human epidermal growth factor receptor 2-positive	<b>PTH1</b>	parathyroid hormone 1
<b>BioPharma</b>	BioPharmaceuticals	<b>HER2-low</b>	human epidermal growth factor receptor 2-low	<b>PTHr1</b>	parathyroid hormone receptor 1
<b>BTKi</b>	Bruton's tyrosine kinase	<b>HER2-ultralow</b>	human epidermal growth factor receptor 2-ultralow	<b>PYR</b>	Peak-Year Revenue
<b>C5</b>	complement component 5	<b>HPP</b>	hypophosphatasia	<b>QW</b>	Once-weekly
<b>cam1</b>	camizestrant	<b>HR+</b>	hormone receptor positive	<b>R&amp;D</b>	Research & Development
<b>CD19</b>	cluster of differentiation 19	<b>HSCT-TMA</b>	hematopoietic stem cell transplantation-associated thrombotic microangiopathy	<b>R&amp;I</b>	Respiratory & Immunology
<b>CDK4/6i</b>	cyclin-dependent kinase 4/6 inhibitor	<b>HypoPT</b>	hypoparathyroidism	<b>RC</b>	radioconjugate
<b>CER</b>	constant exchange rates	<b>i.v.</b>	intravenous	<b>rPFS</b>	radiographic progression-free survival
<b>CFO</b>	net cash inflow from operating activities	<b>IgAN</b>	IgA nephropathy	<b>s.c.</b>	subcutaneous
<b>cis</b>	cisplatin	<b>IL-5</b>	interleukin-5	<b>SBP</b>	systolic blood pressure
<b>cis-inel.</b>	cisplatin-ineligible	<b>IO</b>	immuno-oncology	<b>SERD</b>	selective estrogen receptor degrader
<b>CLDN18.2</b>	Claudin-18.2	<b>IRA</b>	Inflation Reduction Act	<b>SG&amp;A</b>	Selling, General & Administrative
<b>CLL</b>	chronic lymphocytic leukaemia	<b>JP</b>	Japan	<b>SGLT2-</b>	sodium-glucose cotransporter 2 inhibitor
<b>CN</b>	China	<b>K+</b>	potassium	<b>Stg</b>	Stage
<b>COPD</b>	chronic obstructive pulmonary disease	<b>LAA</b>	long-acting amylin	<b>TCE</b>	T-cell engager
<b>COVID-19</b>	SARS-CoV-2 virus	<b>LS-SCLC</b>	limited stage small-cell lung cancer	<b>TKI</b>	tyrosine kinase inhibitor
<b>CRSwNP</b>	chronic rhinosinusitis with nasal polyps	<b>M&amp;A</b>	merger and acquisition	<b>TNBC</b>	triple negative breast cancer
<b>CSA-AKI</b>	cardiac surgery-associated acute kidney injury	<b>mAb</b>	monoclonal antibody	<b>TROP2+</b>	trophoblast cell surface antigen 2-positive
<b>CTx</b>	chemotherapy	<b>mBC</b>	metastatic breast cancer	<b>TSLP</b>	thymic stromal lymphopoietin
<b>CTx-naïve</b>	chemotherapy-naïve	<b>MCL</b>	mantle cell lymphoma	<b>Tx</b>	therapy
<b>CVRM</b>	Cardiovascular, Renal and Metabolism	<b>mCRPC</b>	metastatic castration-resistant prostate cancer	<b>u/r</b>	unresectable
<b>DLBCL</b>	diffuse large B-cell lymphoma	<b>mHSPC</b>	metastatic hormone sensitive prostate cancer	<b>UC</b>	urothelial carcinoma
<b>dPTEN</b>	phosphatase and tensin homolog deficient	<b>MIBC</b>	muscle-invasive bladder cancer	<b>uHTN</b>	uncontrolled hypertension
<b>EBITDA</b>	earnings before interest, tax, depreciation and amortisation	<b>mm</b>	millimetre	<b>US</b>	United States
<b>EM</b>	Emerging Markets	<b>NF1-PN</b>	neurofibromatosis type 1-plexiform neurofibromas	<b>V&amp;I</b>	Vaccines & Immune Therapies
<b>EOS</b>	eosinophil	<b>ngSERD</b>	next-generation oral selective estrogen receptor degrader	<b>VBP</b>	volume-based procurement
<b>EPS</b>	earnings per share	<b>NME</b>	new molecular entity	<b>V+H</b>	variable heavy chain antibody
<b>ERoW</b>	Established Rest of World	<b>NMIBC</b>	non-muscle invasive bladder cancer		



### **Confidentiality Notice**

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful.

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK  
+44(0)203 749 5000  
[www.astrazeneca.com](http://www.astrazeneca.com)

